Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to test the safety and efficacy of the combination of lenvatinib, a
drug that can inhibit the growth of supplying vessels around the tumors, and eribulin, a
chemotherapy drug that targets the cancer cell during mitosis, in inoperable or metastatic
adipocytic sarcoma and leiomyosarcoma.